Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its target price lowered by stock analysts at Stifel Nicolaus from $13.00 to $6.00 in a report released on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 10.50% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $11.00 price objective on the stock. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. BMO Capital Markets downgraded shares of Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $8.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and a consensus target price of $10.46.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $5.43 on Wednesday. The company has a market cap of $281.71, a PE ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a one year low of $4.91 and a one year high of $9.93.

In other news, Director L Patrick Gage bought 3,880 shares of the stock in a transaction on Wednesday, November 29th. The stock was bought at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the purchase, the director now directly owns 38,880 shares in the company, valued at $250,776. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TTPH. SG Americas Securities LLC acquired a new stake in Tetraphase Pharmaceuticals in the third quarter valued at approximately $107,000. Brighton Jones LLC acquired a new stake in Tetraphase Pharmaceuticals in the third quarter valued at approximately $108,000. Voya Investment Management LLC boosted its stake in Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Tetraphase Pharmaceuticals in the second quarter valued at approximately $147,000. Finally, Ameriprise Financial Inc. acquired a new stake in Tetraphase Pharmaceuticals in the second quarter valued at approximately $162,000. Institutional investors own 58.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-ttph-price-target-lowered-to-6-00-at-stifel-nicolaus/1865404.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.